Compare Msci Inc (MSCI) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Pfizer Inc — how do they compare? Msci Inc trades at $554.53 (market cap $40.09B), while Pfizer Inc trades at $27.9 (market cap $158.39B). The key difference: Pfizer Inc is far larger — about 4× Msci Inc's market cap, and Pfizer Inc pays the higher dividend (6.19%). Which is the better fit depends on your goals.
| MSCI | PFE | |
|---|---|---|
Market Cap | $40.09B | $158.39B |
Sector | Financials | Health |
52-Week High | $643.83 | $29.02 |
52-Week Low | $511.84 | $23.60 |
Enterprise Value | $46.25B | $209.89B |
Dividend Yield | 1.49% | 6.19% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $551.39, down 3.77% over 24 hours amid a bearish technical signal. The stock shows strong fundamentals with a 40.73% net income margin and consistent revenue growth, reaching $3.13B in 2025. Recent Q2 2026 earnings slightly missed expectations, but the company maintains robust profitability and a $2.05 dividend. Analyst consensus is bullish with a $728.14 price target, though technical indicators suggest near-term pressure with support at $545.
Outlook remains positive driven by high-margin recurring revenue and strategic acquisitions like First Street. Risks include elevated debt levels and market sensitivity. Institutional sentiment is strong with 73% buy ratings, positioning MSCI for long-term growth despite current technical weakness.
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
